AHRQ: More evidence needed on DMARD use in juvenile arthritis

09/28/2011 | HealthDay News

Although disease-modifying anti-rheumatic drugs appear to be more effective for treating juvenile idiopathic arthritis than ibuprofen or steroids, not much evidence concerning long-term use exists, according to the Agency for Healthcare Research and Quality. Data indicated better health outcomes in children who received DMARDs, but the researchers noted that there was insufficient data to compare different classes of DMARDs.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI